

Xenon Pharmaceuticals Inc.  
Form SC 13G  
July 13, 2018

**SCHEDULE  
13G  
Under the  
Securities  
Exchange Act of  
1934**

**Xenon  
Pharmaceuticals  
Inc.**  
(Name of Issuer)

**Common Stock**  
(Title of Class of  
Securities)

**98420N105**  
(CUSIP Number)

**July 12, 2018**  
(Date of Event  
which Requires  
Filing of this  
Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\*

Edgar Filing: Xenon Pharmaceuticals Inc. - Form SC 13G

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 98420N105

**1** NAMES OF REPORTING PERSONS  
**Vivo Opportunity, LLC**  
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A  
**2** GROUP (See Instructions)  
 (a)  
 (b)  
**3** SEC USE ONLY  
  
**4** CITIZENSHIP OR PLACE OF ORGANIZATION  
**Delaware**  
  
**5** SOLE VOTING POWER  
**1,048,333** <sup>(1)</sup>  
 NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  
**6** SHARED VOTING POWER  
**0**  
**8** SOLE DISPOSITIVE POWER  
**0**  
  
**9** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
**1,048,333** <sup>(1)</sup>  
**10** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

**11** PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (9)  
**5.6%** <sup>(2)</sup>

**12** TYPE OF REPORTING  
PERSON (See  
Instructions)  
**OO**

(1) Based on (i) 48,583 shares of common stock of the Issuer purchased by Vivo Opportunity Fund, L.P. on the open market on July 12, 2018; and (ii) 999,750 shares of common stock of the Issuer purchased by Vivo Opportunity Fund, L.P. in connection with the Issuer's at-the-market offering on July 12, 2018. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P.

(2) Based on (i) 17,658,292 shares of common stock of the Issuer outstanding as of July 10, 2018, as disclosed in the prospectus supplement filed by the Issuer on July 12, 2018, pursuant to Rule 424(b)(5), which forms part of the Issuer's Registration Statement on Form S-3 (File No. 333-208376); and (ii) a total of 1,048,333 shares of common stock of the Issuer purchased by Vivo Opportunity Fund, L.P. on July 12, 2018.

Item 1. (a) Name of Issuer:

Xenon Pharmaceuticals Inc

(b) Address of Issuer's Principal Executive Offices:

200-3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8

Item 2. (a) Name of Person Filing:

Vivo Opportunity, LLC

(b) Address of Principal Business Office or, if None, Residence:

505 Hamilton Avenue, Suite 207, Palo Alto, CA 94301

(c) Citizenship:

Vivo Opportunity, LLC is a Delaware limited liability company.

(d) Title of Class of Securities:

Common Stock

(e) CUSIP Number:

98420N105

Item 3. If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

- (a) Broker or dealer registered under Section 15 of the Act.
- (b) Bank as defined in Section 3(a)(6) of the Act.
- (c) Insurance company as defined in Section 3(a)(19) of the Act.
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940.
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(j), please specify the type of institution:

\_\_\_\_\_

Not Applicable.

Item 4.

Ownership.

(a) Amount beneficially owned:

The shares of common stock are held of record by Vivo Opportunity Fund, L.P.

Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Frank Kung, Albert Cha, Shan Fu, Gaurav Aggarwal and Michael Chang, none of whom has individual voting or investment power with respect to these shares of common stock and each of whom disclaims beneficial ownership of such shares of common stock.

(b) Percent of class:

5.6%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: 1,048,333

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 1,048,333

(iv) Shared power to dispose of or to direct the disposition of: 0

Item 5.

Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.



SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Vivo Opportunity,  
LLC**

July 13, 2018  
(Date)

/s/ Gaurav Aggarwal  
(Signature)

Managing Member  
(Title)